Test Price
2,800 AED✅ Home Collection Available
SCN11A Gene Episodic Pain Syndrome Type 3 Familial Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Test Overview & Methodology
The SCN11A NGS test sequences the entire coding region of the SCN11A gene to detect pathogenic variants associated with familial episodic pain syndrome type 3 (paroxysmal extreme pain disorder). Definitive molecular diagnosis guides targeted therapy and enables accurate family risk assessment.
| Feature | Our SCN11A NGS Test | Closest Alternative |
|---|---|---|
| Precision | Full gene sequencing with >99% analytical sensitivity, including deep intronic and splice-site regions | Sanger sequencing (limited to hotspot exons, lower resolution for novel variants) |
| Methodology | NGS (Next-Generation Sequencing) with bioinformatic pipeline validated against international standards | Sanger sequencing or targeted mutation panel |
| Turnaround Time | 3–4 Weeks (expedited 2‑week option for urgent clinical scenarios) | 4–6 Weeks |
| Clinical Support | Included: Pre-test genetic counselling, post-test clinician interpretation, and family pedigree charting | Often limited to raw report without clinical correlation |
Physician Insight & Safety Protocols
"A positive SCN11A result must be integrated with the patient's clinical phenotype, family history, and neurophysiological findings. I ensure every patient receives pre- and post-test genetic counselling, empowering them with accurate molecular diagnosis without undue anxiety."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory
Do not stop or adjust any prescribed anticonvulsant, analgesic, or neuropathic pain medication without consulting your doctor. Genetic results may inform future therapy but must never lead to abrupt self-adjustment.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Inability to provide a venous blood sample or FTA card spot with adequate DNA yield; ongoing therapeutic anticoagulation (must be managed by the referring physician).
- Exclusion: Patients under guardianship who cannot provide informed consent through a legally authorised representative.
- Red Flag: If you experience sudden vision loss, acute respiratory distress, or severe autonomic instability (unexplained sweating, heart rate >120 bpm at rest) – proceed immediately to the nearest emergency department; these are not typical of episodic pain syndrome and require urgent evaluation.
- Red Flag: Test results indicating a variant of uncertain significance (VUS) should be re-interpreted in a multi-disciplinary genetics board; do not use them as sole basis for surgical or irreversible treatment decisions.
Patient FAQ & Clinical Guidance
1. Why is an SCN11A genetic test necessary if my symptoms are episodic?
Episodic pain syndromes can mimic other neurological conditions. Identifying a pathogenic SCN11A variant provides definitive diagnosis, guides targeted therapy, and enables accurate family risk assessment.
2. How long does the test take, and what sample is required?
The test requires a simple blood draw, extracted DNA, or a dried blood spot on an FTA card. Results are typically released within 3 to 4 weeks; an urgent 2‑week option is available.
3. Will the test be covered by my UAE health insurance?
Many UAE insurers cover medically necessary genetic testing for neurological disorders when pre‑authorised. Our team verifies your policy and handles direct billing via WhatsApp.
UAE Regulatory & Data Privacy Adherence
Data Protection: Patient health information is processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Clinical Safety & Consent: All genetic testing procedures and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Accreditations: ISO 9001:2015 – Certificate INT/EGQ/2509DA/3139. Laboratory operates under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | SCN11A Gene Episodic Pain Syndrome Type 3 Familial Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks (expedited 2‑week option available for urgent cases) |
| Sample Type / Matrix | Peripheral whole blood, extracted DNA, or dried blood spot (FTA card) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM–11 PM |
| Methodology Used | Next-Generation Sequencing (NGS) with bioinformatic pipeline covering full gene coding region including deep intronic and splice-site regions |
| ICD-10-CM Code | G90.89, Z15.89, Z82.2 |
| LOINC Code | 81223-8 |
| DHA Facility License & Laboratory Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians